MCID: WLM011
MIFTS: 22

Wilms Tumor 6

Categories: Genetic diseases, Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 6

MalaCards integrated aliases for Wilms Tumor 6:

Name: Wilms Tumor 6 54 71
Wilms Tumor 6, Susceptibility to 71
Susceptibility to Wilms Tumor 6 71
Wilms Tumor, Susceptibility to 71
Wt6 71

Classifications:



External Ids:

OMIM 54 616806
MedGen 40 CN235182
MeSH 42 D009396
SNOMED-CT via HPO 65 25081006 302849000

Summaries for Wilms Tumor 6

UniProtKB/Swiss-Prot : 71 Wilms tumor 6: A pediatric malignancy of kidney, and the most common childhood abdominal malignancy. It is caused by the uncontrolled multiplication of renal stem, stromal, and epithelial cells.

MalaCards based summary : Wilms Tumor 6, is also known as wilms tumor 6, susceptibility to, and has symptoms including nephroblastoma An important gene associated with Wilms Tumor 6 is REST (RE1 Silencing Transcription Factor). The drugs Cyclophosphamide and Dactinomycin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, kidney and t cells.

Description from OMIM: 616806

Related Diseases for Wilms Tumor 6

Symptoms & Phenotypes for Wilms Tumor 6

Clinical features from OMIM:

616806

Human phenotypes related to Wilms Tumor 6:

32
id Description HPO Frequency HPO Source Accession
1 nephroblastoma 32 HP:0002667

Drugs & Therapeutics for Wilms Tumor 6

Drugs for Wilms Tumor 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Dactinomycin Approved Phase 3 50-76-0 2019 457193
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
7
Lenograstim Approved Phase 3,Phase 1 135968-09-1
8
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
9
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
10
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
11
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
12 Alkylating Agents Phase 3,Phase 2,Phase 1
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 3,Phase 1,Phase 2
16 Antimitotic Agents Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Antirheumatic Agents Phase 3,Phase 1,Phase 2
19 Etoposide phosphate Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 3
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
24 Liver Extracts Phase 3,Phase 2,Phase 1
25 Gemtuzumab Phase 2, Phase 3
26
Acetaminophen Approved Phase 1, Phase 2 103-90-2 1983
27
Diphenhydramine Approved Phase 1, Phase 2 58-73-1, 147-24-0 3100
28
Histamine Approved, Investigational Phase 1, Phase 2 75614-87-8, 51-45-6 774
29
Promethazine Approved Phase 1, Phase 2 60-87-7 4927
30
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
31
Mechlorethamine Approved Phase 2,Phase 1 51-75-2 4033
32
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
33
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
34
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
35
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
36
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
39
Vidarabine Approved Phase 1, Phase 2 24356-66-9 32326 21704
40
Epirubicin Approved Phase 2 56420-45-2 41867
41
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
42
Fluorouracil Approved Phase 2 51-21-8 3385
43
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
44
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
45
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
46
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
47
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
48 Vaccines Phase 1, Phase 2
49 Analgesics Phase 1, Phase 2
50 Analgesics, Non-Narcotic Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 54)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
2 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
3 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3 FLAIMy - Fluda, Ida, Ara-C, Mylotarg
4 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3 gemtuzumab ozogamycin
5 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
6 Acute Effect of Continuous Positive Airway Pressure in Heart Failure Completed NCT01088854 Phase 2
7 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
8 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2 GM-CSF (Sargramostim)
9 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
10 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
11 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Completed NCT01222780 Phase 1, Phase 2 Marqibo
13 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
14 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
15 Autologous Dendritic Cell Vaccination in Mesothelioma Recruiting NCT02649829 Phase 1, Phase 2
16 DC Vaccination for Post-remission Therapy in AML Recruiting NCT02405338 Phase 1, Phase 2
17 Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients Recruiting NCT02649582 Phase 1, Phase 2
18 A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy Recruiting NCT03149003 Phase 2 DSP-7888 Dosing Emulsion;Bevacizumab
19 Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT01266083 Phase 2
20 Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 Active, not recruiting NCT01890980 Phase 2
21 Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia Not yet recruiting NCT02770820 Phase 1, Phase 2
22 WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation Suspended NCT01334060 Phase 2
23 WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Suspended NCT01621724 Phase 1, Phase 2
24 Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Suspended NCT01640301 Phase 1, Phase 2 Cyclophosphamide;Fludarabine Phosphate
25 Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer Terminated NCT01220128 Phase 2 Placebo;Aromatase inhibitor;5-Fluorouracil;Carboplatin AUC;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Trastuzumab
26 Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission Completed NCT00834002 Phase 1
27 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Completed NCT01169584 Phase 1 Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
28 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Completed NCT00398138 Phase 1
29 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Completed NCT00020150 Phase 1 O6-benzylguanine;temozolomide
30 Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides Completed NCT01598454 Phase 1 racotumomab
31 Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1 carboplatin;etoposide;ifosfamide
32 CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Recruiting NCT01995708 Phase 1
33 A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer Recruiting NCT02737787 Phase 1 Nivolumab
34 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Recruiting NCT02498665 Phase 1 DSP-7888 Dosing Emulsion
35 A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Recruiting NCT02536183 Phase 1 Lyso-thermosensitive liposomal doxorubicin
36 Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies Recruiting NCT02392793 Phase 1 Talazoparib;Irinotecan;Temozolomide;Filgrastim;Peg-filgrastim
37 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
38 Administration of Donor MultiTAA-Specific T Cells for ALL Recruiting NCT02475707 Phase 1
39 Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Recruiting NCT02494167 Phase 1
40 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Recruiting NCT00931931 Phase 1
41 Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML Recruiting NCT02750995 Phase 1 Azacitidine
42 Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors Recruiting NCT02789228 Phase 1
43 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation Active, not recruiting NCT00620633 Phase 1
44 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/ Active, not recruiting NCT00562640 Phase 1 cyclophosphamide
45 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
46 Study in Children With the Diagnosis of Congenital Diaphragmatic Hernia (CDH) and Oesophageal Atresia (EA) Completed NCT02466451
47 Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor Completed NCT01576211
48 Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms Completed NCT00665002 Montanide;Sargramostim (GM-CSF)
49 Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors Completed NCT01004783
50 Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions Completed NCT00758108

Search NIH Clinical Center for Wilms Tumor 6

Genetic Tests for Wilms Tumor 6

Anatomical Context for Wilms Tumor 6

MalaCards organs/tissues related to Wilms Tumor 6:

39
Myeloid, Kidney, T Cells, Liver, Bone, Heart, Placenta

Publications for Wilms Tumor 6

Variations for Wilms Tumor 6

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 6:

71
id Symbol AA change Variation ID SNP ID
1 REST p.Arg160Pro VAR_076333
2 REST p.Asn290Tyr VAR_076334
3 REST p.His322Arg VAR_076335 rs869025312
4 REST p.His412Gln VAR_076336

ClinVar genetic disease variations for Wilms Tumor 6:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 REST NM_005612.4(REST): c.831_832delAT (p.Cys278Trpfs) deletion risk factor rs869025310 GRCh38 Chromosome 4, 56911469: 56911470
2 REST NM_005612.4(REST): c.773_776delTGAG (p.Val258Alafs) deletion risk factor rs869025311 GRCh38 Chromosome 4, 56911411: 56911414
3 REST NM_005612.4(REST): c.965A> G (p.His322Arg) single nucleotide variant risk factor rs869025312 GRCh38 Chromosome 4, 56919853: 56919853

Expression for Wilms Tumor 6

Search GEO for disease gene expression data for Wilms Tumor 6.

Pathways for Wilms Tumor 6

GO Terms for Wilms Tumor 6

Sources for Wilms Tumor 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....